BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38281880)

  • 1. Spatial heterogeneity of tumor cells and the tissue microenvironment in oral squamous cell carcinoma.
    Steffen C; Schallenberg S; Dernbach G; Dielmann A; Dragomir MP; Schweiger-Eisbacher C; Klauschen F; Horst D; Tinhofer I; Heiland M; Keilholz U
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2024 Apr; 137(4):379-390. PubMed ID: 38281880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma.
    Kikuchi M; Yamashita D; Hara S; Takebayashi S; Hamaguchi K; Mizuno K; Omori K; Shinohara S
    Head Neck; 2021 Feb; 43(2):534-543. PubMed ID: 33029887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression and Tumour Microenvironment Patterns in Resected Non-Small-Cell Lung Cancer.
    Gurevičienė G; Matulionė J; Poškienė L; Miliauskas S; Žemaitis M
    Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541208
    [No Abstract]   [Full Text] [Related]  

  • 4. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
    Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
    Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical Analysis of Foxp3
    Stasikowska-Kanicka O; Wągrowska-Danilewicz M; Danilewicz M
    Pathol Oncol Res; 2018 Jul; 24(3):497-505. PubMed ID: 28669079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
    Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
    Front Immunol; 2021; 12():798424. PubMed ID: 35145511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
    Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
    Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
    Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
    Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
    Sun Z; Nyberg R; Wu Y; Bernard B; Redmond WL
    PLoS One; 2021; 16(2):e0247238. PubMed ID: 33596250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial Profiles of Intratumoral PD-1
    Yoshimura K; Tsujikawa T; Mitsuda J; Ogi H; Saburi S; Ohmura G; Arai A; Shibata S; Thibault G; Chang YH; Clayburgh DR; Yasukawa S; Miyagawa-Hayashino A; Konishi E; Itoh K; Coussens LM; Hirano S
    Front Immunol; 2021; 12():769534. PubMed ID: 34777389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between spatial distribution of leukocyte subsets and clinical presentation of head and neck squamous cell carcinoma.
    Netzer C; von Arps-Aubert V; Mačinković I; von der Grün J; Küffer S; Ströbel P; von Knethen A; Weigert A; Beutner D
    Front Immunol; 2023; 14():1240394. PubMed ID: 38322012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort.
    William WN; Zhang J; Zhao X; Parra ER; Uraoka N; Lin HY; Peng SA; El-Naggar AK; Rodriguez-Canales J; Song J; Gillenwater AM; Wistuba II; Myers JN; Gold KA; Ferrarotto R; Hwu P; Davoli T; Lee JJ; Heymach JV; Papadimitrakopoulou VA; Lippman SM
    Cancer; 2023 Mar; 129(5):714-727. PubMed ID: 36597662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
    Satgunaseelan L; Gupta R; Madore J; Chia N; Lum T; Palme CE; Boyer M; Scolyer RA; Clark JR
    Pathology; 2016 Oct; 48(6):574-80. PubMed ID: 27590194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
    Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
    BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients.
    Parra ER; Behrens C; Rodriguez-Canales J; Lin H; Mino B; Blando J; Zhang J; Gibbons DL; Heymach JV; Sepesi B; Swisher SG; Weissferdt A; Kalhor N; Izzo J; Kadara H; Moran C; Lee JJ; Wistuba II
    Clin Cancer Res; 2016 Dec; 22(24):6278-6289. PubMed ID: 27252415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterisation of tumour-immune phenotypes and PD-L1 positivity in squamous bladder cancer.
    Jung M; Rose M; Knuechel R; Loeffler C; Muti H; Kather JN; Gaisa NT;
    BMC Cancer; 2023 Feb; 23(1):113. PubMed ID: 36726072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personal immune profiles: Diversity and prognostic value for oral tongue squamous cell carcinoma evaluated by comprehensive immune parameter analyses with multiplex immunofluorescence.
    Daroonpan P; Ouchi R; Zhang C; Nagai S; Nishii N; Kashima Y; Tsushima F; Harada H; Hamagaki M; Ikeda T; Aida J; Kaomongkolgit R; Azuma M
    Oral Oncol; 2023 Aug; 143():106458. PubMed ID: 37329869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.
    Tosi A; Parisatto B; Menegaldo A; Spinato G; Guido M; Del Mistro A; Bussani R; Zanconati F; Tofanelli M; Tirelli G; Boscolo-Rizzo P; Rosato A
    J Exp Clin Cancer Res; 2022 Sep; 41(1):279. PubMed ID: 36123711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.